NEW YORK, NY--(Marketwired - Nov 15, 2013) - Daxor Corporation (
The Board of Directors has approved payment of a dividend of $0.05 per share. The dividend will be paid on Friday, December 27th to shareholders of record on Monday, December 9th.
Daxor manufactures and markets the BVA-100 Blood Volume Analyzer which is used in conjunction with Volumex, Daxor's single use diagnostic kit. The BVA-100 provides key information that can be used to diagnose and treat various medical conditions including congestive heart failure, hypertension, anemia, blood loss during surgery, trauma, and shock (collapse of blood pressure).
At the present time, physicians must treat these conditions by guessing whether or not they are due to volume expansions or contractions. The Blood Volume Analyzer allows precise quantitation of patients' total blood volume and red blood cell volume, which takes the guesswork out of this process. Appropriate therapies can then be employed to correct excesses or deficits in volume, leading to better outcomes for patients.
Daxor provides a unique frozen blood storage program for individuals through its Idant Laboratories subsidiary which allows them to store their own blood for up to ten years. This is a major advantage over refrigerated blood which can only be stored for up to 42 days. It has been proven that if someone needs a transfusion, the safest blood to use is their own. The freezing and restoring of blood requires highly specialized technology.
For more information regarding Daxor's Blood Volume Analyzer BVA-100, visit the Company's website at www.Daxor.com.